Search results
Results from the WOW.Com Content Network
For example, gentamicin is an antibiotic that can be nephrotoxic (kidney damaging) and ototoxic (hearing damaging); measurement of gentamicin through concentrations in a patient's plasma and calculation of the AUC is used to guide the dosage of this drug. [3] AUC becomes useful for knowing the average concentration over a time interval, AUC/t.
Vancomycin is a glycopeptide antibiotic medication used to treat certain bacterial infections. [7] It is administered intravenously (injection into a vein) to treat complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant Staphylococcus aureus. [8]
Dalbavancin, sold under the brand names Dalvance in the US and Xydalba in the EU (both by AbbVie) among others, is a second-generation lipoglycopeptide antibiotic medication. It belongs to the same class as vancomycin, the most widely used and one of the treatments available to people infected with methicillin-resistant Staphylococcus aureus ...
Other methods of prevention include hand washing to prevent infection, prompt treatment of worsening respiratory symptoms, and not smoking. [10] [19] Treatment depends on the underlying cause. [20] Pneumonia believed to be due to bacteria is treated with antibiotics. [11] If the pneumonia is severe, the affected person is generally hospitalized ...
Piperacillin is a broad-spectrum β-lactam antibiotic of the ureidopenicillin class. [1] The chemical structure of piperacillin and other ureidopenicillins incorporates a polar side chain that enhances penetration into Gram-negative bacteria and reduces susceptibility to cleavage by Gram-negative beta lactamase enzymes.
The pneumonia severity index (PSI) or PORT Score is a clinical prediction rule that medical practitioners can use to calculate the probability of morbidity and mortality among patients with community acquired pneumonia. [1] The PSI/PORT score is often used to predict the need for hospitalization in people with pneumonia. [2]
Rates of Mycoplasma pneumonia in all global community-acquired pneumonia (CAP) cases range from 10-15%. [13] [14] The rate of Mycoplasma pneumonia in adults with CAP is estimated to be 15%, and the rate of in children with CAP has been reported at 27.4%. [3] The rates of M. pneumoniae among hospitalized CAP cases are 35% in adults [14] and 24% ...
It has an elimination half-life of 2-3 hours in adults, which is prolonged in renal failure. Approved indications include community acquired pneumonia, uncomplicated skin and skin structure infections, and uncomplicated urinary tract infections. It was patented in 1980 and approved for medical use in 1989. [1]